Postoperative Use of Bevacizumab as an Antifibrotic Agent in Glaucoma Filtration Surgery in the Rabbit
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
PURPOSE: To evaluate the efficacy of bevacizumab as an antifibrotic agent after trabeculectomy in rabbits. METHODS: Forty-two rabbits underwent trabeculectomy and were randomly assigned to receive a postoperative course of seven subconjunctival injections of bevacizumab (1.25 mg, 25 mg/mL), 5-fluorouracil (5-FU; 5 mg, 50 mg/mL), or balanced salt solution (BSS; 0.1 mL, control). Bleb survival and characteristics were evaluated over a 30-day period. The animals were killed on postoperative day (PD)10, PD20, and PD30. Histology and immunohistochemistry of the surgical eyes was performed to evaluate and grade the amount of scarring and fibrosis in each group. RESULTS: Bevacizumab significantly improved the outcome of filtration surgery in this model. Bevacizumab prolonged bleb survival compared with the 5-FU and control groups (16.0 +/- 1.3 days vs. 6.9 +/- 0.6 and 7.4 +/- 0.85 days, respectively; P < 0.001). Bevacizumab-treated eyes had significantly larger and higher blebs than the control and 5-FU-treated groups (P < 0.05). Histologic analysis revealed that eyes treated with bevacizumab had significantly less postoperative scarring at the microscopic level at PD10 and PD20 (P = 0.009). CONCLUSIONS: Postoperative subconjunctival injection of bevacizumab is associated with improved trabeculectomy bleb survival in the rabbit model. Bevacizumab may be a useful agent for improving success and limiting scar tissue formation after trabeculectomy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Bevacizumab is reported to have antifibrotic activity that reduces scar formation in glaucoma filtration surgery.29–31”
From Risk of Scar in the Comparison of Age-related Macular Degeneration Treatments Trials (2014) · cites this paper as [31]
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968 · cited 1×
“Bevacizumab is an antibody against VEGF that has been approved by the US Food and Drug Administration for the treatment of colorectal cancer.(11) Several case reports have described the successful, off-label intravitreal use of bevacizumab for treatment of neovascularization associated with proliferative diabetic reti…”
Vascular Endothelial Growth Factor and Angiogenesis
Hoeben, A., Landuyt, B., Highley, M. S., Wildiers, H., Van Oosterom, A. T., & De Bruijn, E. A. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.4.3 · Cited by 1,824
Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration
Avery, R. L., Pieramici, D. J., Rabena, M. D., Castellarin, A. A., Nasir, M. A., & Giust, M. J. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2005.11.019 · Cited by 1,133
Angiogenesis in wound repair: Angiogenic growth factors and the extracellular matrix
Li, J., Zhang, Y., & Kirsner, R. S. (2003) · Microscopy Research and Technique · doi:10.1002/jemt.10249 · Cited by 740 · cited 1×
“Angiogenesis, which allows for early migration of inflammatory cells and fibroblasts into the wound and the release of key mitogenic cytokines such as fibroblast growth factor, is a critical component of the wound-healing process.(8,9) Vascular endothelial growth factor (VEGF) is one of the most potent cytokines in wo…”
Wound healing in glaucoma filtering surgery
Skuta, G. L., & Parrish, R. K. (1987) · Survey of Ophthalmology · doi:10.1016/0039-6257(87)90091-9 · Cited by 630 · cited 1×
“The most common reason for trabeculectomy failure is the development of fibrosis in the conjunctiva and episclera because of progressive fibroblast proliferation and collagen deposition at the site of the filtration bleb.(1,2) This frequently leads to poor postoperative intraocular pressure control with subsequent pro…”
Asahara, T., Bauters, C., Zheng, L. P., Takeshita, S., Bunting, S., Ferrara, N., Symes, J. F., & Isner, J. M. (1995) · Circulation · doi:10.1161/01.cir.92.9.365 · Cited by 596 · cited 1×
“Angiogenesis, which allows for early migration of inflammatory cells and fibroblasts into the wound and the release of key mitogenic cytokines such as fibroblast growth factor, is a critical component of the wound-healing process.(8,9) Vascular endothelial growth factor (VEGF) is one of the most potent cytokines in wo…”
Five-year Follow-up of the Fluorouracil Filtering Surgery Study
THE FLUOROURACIL FILTERING SURGERY STUDY GROUP (1996) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(14)70431-3 · Cited by 526
Migdal, C., Gregory, W., & Hitchings, R. (1994) · Ophthalmology · doi:10.1016/s0161-6420(94)31120-1 · Cited by 373
Regulation of scar formation by vascular endothelial growth factor
Wilgus, T. A., Ferreira, A. M., Oberyszyn, T. M., Bergdall, V. K., & DiPietro, L. A. (2008) · Laboratory Investigation · doi:10.1038/labinvest.2008.36 · Cited by 319
Effects of 5-fluorouracil and Mitomycin C on Cultured Rabbit Subconjunctival Fibroblasts
Yamamoto, T., Varani, J., Soong, H. K., & Lighter, P. R. (1990) · Ophthalmology · doi:10.1016/s0161-6420(90)32456-9 · Cited by 271
Cited by
Risk of Scar in the Comparison of Age-related Macular Degeneration Treatments Trials
Daniel, E., Toth, C. A., Grunwald, J. E., Jaffe, G. J., Martin, D. F., Fine, S. L., Huang, J., Ying, G.-S., Hagstrom, S. A., Winter, K., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.10.019 · Cited by 335
Conjunctival fibrosis following filtering glaucoma surgery
Schlunck, G., Meyer-ter-Vehn, T., Klink, T., & Grehn, F. (2016) · Experimental Eye Research · doi:10.1016/j.exer.2015.03.021 · Cited by 175
“Several studies suggested to use VEGF antagonists as antifibrotic agents in glaucoma surgery (Grewal et al., 2008; How et al., 2010; Li et al., 2009; Memarzadeh et al., 2009; Van Bergen et al., 2011).”
BackgroundWound Modulation After Filtration Surgery
Seibold, L. K., Sherwood, M. B., & Kahook, M. Y. (2012) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2012.01.008 · Cited by 167
The Changing Conceptual Basis of Trabeculectomy: A Review of Past and Current Surgical Techniques
Razeghinejad, R., Fudemberg, S. J., & Spaeth, G. L. (2011) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2011.07.005 · Cited by 153
Subconjunctival Bevacizumab Versus Mitomycin C Adjunctive to Trabeculectomy
Nilforushan, N., Yadgari, M., Kish, S. K., & Nassiri, N. (2011) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2011.08.005 · Cited by 128
Modulation of Fibroblasts in Conjunctival Wound Healing
Zada, M., Pattamatta, U., & White, A. J. R. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2017.08.028 · Cited by 114
The role of different VEGF isoforms in scar formation after glaucoma filtration surgery
Bergen, T. V., Vandewalle, E., de Veire, S. V., Dewerchin, M. A., Stassen, J., Moons, L., & Stalmans, I. (2011) · Experimental Eye Research · doi:10.1016/j.exer.2011.08.016 · Cited by 93
“However, this is in keeping with the previous literature describing this model for subconjunctival scarring (Cordeiro et al., 2003; Mead et al., 2003; Memarzadeh et al., 2009), and can be explained by the fact that the surgery is performed on non-glaucomatous rabbit eyes with normal IOPs at baseline.”
BackgroundResultEvaluation of Pirfenidone as a New Postoperative Antiscarring Agent in Experimental Glaucoma Surgery
Zhong, H., Sun, G., Lin, X., Wu, K., & Yu, M. (2011) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.10-6240 · Cited by 90
Antifibrotic activity of bevacizumab on human Tenon's fibroblasts in vitro
O'Neill, E. C., Qin, Q., Van Bergen, N. J., Connell, P. P., Vasudevan, S., Coote, M. A., Trounce, I. A., Wong, T. T. L., & Crowston, J. G. (2010) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-5669 · Cited by 73
How, A. C. S., Chua, J., Charlton, A., Su, R., Lim, M. C. C., Kumar, R. S., Crowston, J. G., & Wong, T. T. L. (2010) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.09-3949 · Cited by 72
“A recent study has reported on the reduction of subconjunctival scarring in vivo with the use of bevacizumab.(18) However, following on from this report, we present evidence that the antifibrotic effect of From the (1)Singapore National Eye Centre, Singapore; the (2)Department of Pathology, National University Hospita…”
BackgroundIntracameral bevacizumab as an adjunct to trabeculectomy: a 1-year prospective, randomised study
Vandewalle, E., Pinto, L. A., Bergen, T. V., Spielberg, L. H., Fieuws, S., Moons, L., Spileers, W., Zeyen, T. G., & Stalmans, I. (2013) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2013-303966 · Cited by 74
Lockwood, A., Brocchini, S., & Khaw, P. T. (2012) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.10.008 · Cited by 74
Novel Drug Delivery Systems Fighting Glaucoma: Formulation Obstacles and Solutions
Rahić, O., Tucak, A., Omerović, N., Sirbubalo, M., Hindija, L., Hadžiabdić, J., & Vranić, E. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics13010028 · Cited by 73
Angiogenesis in glaucoma filtration surgery and neovascular glaucoma: A review
Kim, M., Lee, C., Payne, R. M., Yue, B. Y. J. T., Chang, J.-H., & Ying, H. (2015) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2015.04.003 · Cited by 69
Sengupta, S., Venkatesh, R., & Ravindran, R. D. (2011) · Journal of Glaucoma · doi:10.1097/ijg.0b013e31821826b2 · Cited by 60
Xi, L., Wang, T., Zhao, F., Zheng, Q., Li, X., Luo, J., Liu, J., Quan, D., & Ge, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100632 · Cited by 63
Tear Cytokine Profile in Medicated Glaucoma Patients
Chong, R. S., Jiang, Y., Boey, P. Y., Yu, S. J., Htoon, H. M., Aung, T., Khaw, P. T., & Wong, T. T. L. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2010.03.064 · Cited by 61
Recent Advances in the Management of Neovascular Glaucoma
SooHoo, J. R., Seibold, L. K., & Kahook, M. Y. (2013) · Seminars in Ophthalmology · doi:10.3109/08820538.2012.730103 · Cited by 60
Improving patient outcomes following glaucoma surgery: state of the art and future perspectives
Bergen, T. V., de Velde, S. V., Vandewalle, E., Moons, L., & Stalmans, I. (2014) · Clinical ophthalmology · doi:10.2147/opth.s48745 · Cited by 57
“53 When compared with blebs treated with 5-fluorouracil (5 mg), those treated with the VEGF inhibitor (1.25 mg) survived longer, 59 and combining bevacizumab (2.5 mg) and 5-fluorouracil (5 mg) resulted in 100% bleb survival and a greater antifibrotic effect compared with monotherapy using each…”
InfluentialCurrent Perspectives on the Use of Anti-VEGF Drugs as Adjuvant Therapy in Glaucoma
Andrés‐Guerrero, V., Perucho-Gonzalez, L., Garcia-Sanchez, J., Morales‐Fernández, L., Saenz-Frances, F., Herrero‐Vanrell, R., Pablo, L. E., Polo, V., Martínez-de-la-Casa, J. M., & Konstas, A.-G. P. (2016) · Advances in Therapy · doi:10.1007/s12325-016-0461-z · Cited by 59
“25 mg BVZ, 5-FU, or balanced salt solution (BSS; control) was performed in rabbits (n = 42) that underwent trabeculectomy [78].”
BackgroundMethodResultInfluentialTargeted Ocular Drug Delivery with Pharmacokinetic/Pharmacodynamic Considerations
Shen, J., Lu, G. W., & Hughes, P. M. (2018) · Pharmaceutical Research · doi:10.1007/s11095-018-2498-y · Cited by 59
Akkan, J. C. U., & Cilsim, S. (2013) · Journal of Glaucoma · doi:10.1097/ijg.0b013e318287abf3 · Cited by 58
Yu‐Wai‐Man, C., & Khaw, P. T. (2014) · Expert Review of Ophthalmology · doi:10.1586/17469899.2015.983475 · Cited by 46
“Bevacizumab is a recombinant humanized monoclonal antibody against VEGF, and several studies have shown that it decreases scar formation and prolongs bleb survival after experimental glaucoma filtration surgery [12,14,15].”
BackgroundStahnke, T., Löbler, M., Kästner, C., Stachs, O., Wree, A., Sternberg, K., Schmitz, K., & Guthoff, R. F. (2012) · Experimental Eye Research · doi:10.1016/j.exer.2012.04.015 · Cited by 44
Current variations of glaucoma filtration surgery
Salim, S. (2012) · Current Opinion in Ophthalmology · doi:10.1097/icu.0b013e32834ff401 · Cited by 42
“Amniotic membrane and antivascular endothelial growth factor (anti-VEGF) agents have been investigated in animal models with improved trabeculectomy bleb survival [23,24].”
BackgroundAnti–Vascular Endothelial Growth Factor Therapy in Glaucoma Filtration Surgery
Mathew, R. G., & Barton, K. (2011) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2011.03.013 · Cited by 43
Bleb vascularity following post‐trabeculectomy subconjunctival bevacizumab: a pilot study
Chua, B., Nguyen, D. Q., Qin, Q., Ruddle, J. B., Wells, A. P., Niyadurupola, N., Gupta, V., Wong, T. T. L., Coote, M., & Crowston, J. G. (2012) · Clinical and Experimental Ophthalmology · doi:10.1111/j.1442-9071.2012.02798.x · Cited by 41
Comparison of the use of 5‐fluorouracil and bevacizumab in primary trabeculectomy: results at 1 year
Jurkowska‐Dudzińska, J., Kosior‐Jarecka, E., & Żarnowski, T. (2011) · Clinical and Experimental Ophthalmology · doi:10.1111/j.1442-9071.2011.02608.x · Cited by 39
“Recent studies with animal models have successfully tested similar doses.(38) In our study, the dosage schedule was consistent with that applied in a phase III study on CAT-152.”
ResultTarget drug delivery system as a new scarring modulation after glaucoma filtration surgery
Shao, T., Li, X., & Ge, J. (2011) · Diagnostic Pathology · doi:10.1186/1746-1596-6-64 · Cited by 38
“However, filtering blebs treated with these agents can still fail through scarring and because of their nonspecific mechanisms of action[5,6], these agents can cause widespread cell death and apoptosis.”
BackgroundThe Role of the MRTF-A/SRF Pathway in Ocular Fibrosis
Yu‐Wai‐Man, C., Treisman, R., Bailly, M., & Khaw, P. T. (2014) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.14-14692 · Cited by 37
Han, Q., Wang, Y., Li, X., Peng, R., Li, A., Qian, Z., & Yu, L. (2015) · Journal of Materials Science Materials in Medicine · doi:10.1007/s10856-015-5556-6 · Cited by 33
Ji, Q., Qi, B. B., Liu, L., Guo, X., & Zhong, J. (2014) · Journal of Glaucoma · doi:10.1097/ijg.0000000000000147 · Cited by 33
Anti-VEGF therapy for the treatment of glaucoma: a focus on ranibizumab and bevacizumab
Park, S. C., Su, D., & Tello, C. A. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.721772 · Cited by 33
“[48] reported significantly improved bleb survival in rabbit eyes with subconjunctival injections of 1.”
BackgroundYe, H.-H., Qian, Y., Lin, M., Duan, Y., Sun, X., Zhuo, Y., & Ge, J. (2010) · PubMed Central · Cited by 33
Freiberg, F. J., Matlach, J., Grehn, F. J., Klink, & Karl, K. (2013) · Clinical ophthalmology · doi:10.2147/opth.s41750 · Cited by 34
“Memarzadeh et al reported a significant reduction in postoperative scarring on a microscopic level and prolonged bleb survival when comparing bevacizumab to 5-FU and a balanced salt solution, respectively, in rabbits, even though a statistically significant difference in IOP reduction could not be found.(17) Esson et…”
BackgroundLow-dose subconjunctival bevacizumab to augment trabeculectomy for glaucoma
Mostafaei, A., & Sedghipour, M.-R. (2011) · Clinical ophthalmology · doi:10.2147/opth.s17896 · Cited by 30
“11 Human studies are quite limited in this regard.”
Choi, J., Choi, J., & Kim, Y.-D. (2010) · Korean Journal of Ophthalmology · doi:10.3341/kjo.2010.24.1.47 · Cited by 29
“A recent study showed that postoperative subconjunctival injection of bevacizumab was associated with improved trabeculectomy bleb survival in the rabbit model, suggesting bevacizumab may be a useful agent for improving the success rate and limiting scar tissue formation after trabeculectomy [22].”
BackgroundThe Effect of Bevacizumab on Wound Healing Modulation in an Experimental Trabeculectomy Model
Özgönül, C., Mumcuoğlu, T., & Günal, A. (2013) · Current Eye Research · doi:10.3109/02713683.2013.851704 · Cited by 31
“Memarzadeh et al.(28) claimed that the preoperative IOP values of animals are normal and that is why the bleb morphology would demonstrate a difference between groups better, rather than the IOP values.”
BackgroundResultInfluentialThe Effect of Bevacizumab on the Outcome of Trabeculectomy with 5-Fluorouracil
Suh, W., & Kee, C. (2013) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2012.0250 · Cited by 27
Vahedian, Z., Mafi, M., Fakhraie, G., Zarei, R., Eslami, Y., Ghadimi, H., & Mohebbi, M. (2017) · Journal of Glaucoma · doi:10.1097/ijg.0000000000000741 · Cited by 27
Experimental models of glaucoma filtration surgery
Chong, R. S., Crowston, J. G., & Wong, T. T. L. (2020) · Acta Ophthalmologica · doi:10.1111/aos.14485 · Cited by 27
“…versions of trabeculectomy have also been performed with or without the creation of a scleral flap or peripheral iridectomy in rabbits (Perkins et al. 2002; Memarzadeh et al. 2009; Takeuchi et al. 2009; Ekinci et al. 2014), dogs (Kojima et al. 2015) and non-human primate (Ye et al. 2010) species.”
BackgroundThe PLGA Implant as an Antimitotic Delivery System After Experimental Trabeculectomy
Rodríguez-Agirretxe, I., Vega, S. C., Rezola, R., Vecino, E., Mendicute, J., Suarez-Cortes, T. M., & Acera, A. (2013) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.13-11777 · Cited by 26
Butler, M. R., Ponce, C. M. P., Weinstock, Y. E., Orengo-Nania, S. D., Chévez‐Barrios, P., & Frankfort, B. J. (2013) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.13-12047 · Cited by 27
Animal models and drug candidates for use in glaucoma filtration surgery: A systematic review
van Mechelen, R. J. S., Wolters, J. E. J., Bertens, C. J. F., Webers, C. A. B., van den Biggelaar, F. J. H. M., Gorgels, T. G. M. F., & Beckers, H. J. M. (2022) · Experimental Eye Research · doi:10.1016/j.exer.2022.108972 · Cited by 24
Şimşek, T., Çankaya, A. B., & Elgin, U. (2012) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2012.0035 · Cited by 26
Soheilian, M., Tousi, A., & Hasanpour, H. (2016) · Journal of Ophthalmic and Vision Research · doi:10.4103/2008-322x.188390 · Cited by 25
“Although bevacizumab is a well‐known agent in aborting vasoproliferative processes like PDR, reports like studies by Memarzadeh et al[22] and Pennock et al[23] show effectiveness of this molecule in slowing of an avascular process like scar formation or PVR in rabbits.”
Overview of cicatricial modulators in glaucoma fistulizing surgery
de Oliveira, C. M., & Ferreira, J. D. L. M. (2020) · International Ophthalmology · doi:10.1007/s10792-020-01454-w · Cited by 22
Connexin43 Modulation Inhibits Scarring in a Rabbit Eye Glaucoma Trabeculectomy Model
Deva, N. C., Zhang, J., Green, C. R., & Danesh-Meyer, H. V. (2012) · Inflammation · doi:10.1007/s10753-012-9439-4 · Cited by 22
“The main disparity with our results compared to other approaches used previously though was in the assessment of clinical parameters where better success has been reported with bleb presence and prolonged bleb survival in treated animals [39, 41, 43, 50-52].”
BackgroundResultTakeuchi, K., Nakazawa, M., & Ebina, Y. (2011) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.11-7478 · Cited by 22
Deep Sclerectomy With Bevacizumab and Mitomycin C: A Comparative Study
Anand, N., & Bong, C. X. (2013) · Journal of Glaucoma · doi:10.1097/ijg.0b013e3182883c0c · Cited by 21
Wang, Y., Xu, Z., Li, W., Wei, W., Qin, M., Li, Q., Liu, X., Zhang, X., & Wang, X. (2022) · Biomaterials Science · doi:10.1039/d1bm01614h · Cited by 17
Kobayashi, S., Inoue, M., Yamane, S., Sakamaki, K., Arakawa, A., & Kadonosono, K. (2015) · Journal of Glaucoma · doi:10.1097/ijg.0000000000000211 · Cited by 17
Intravitreal ranibizumab as an adjunct for Ahmed valve surgery in open‐angle glaucoma: a pilot study
Desai, R. U., Singh, K., & Lin, S. C. (2012) · Clinical and Experimental Ophthalmology · doi:10.1111/j.1442-9071.2012.02836.x · Cited by 18
Sakarya, Y., Sakarya, R., Kara, S., & Soylu, T. (2011) · Medical Hypotheses · doi:10.1016/j.mehy.2011.04.030 · Cited by 16
“b-Aminoproprionitrile, D-penicillamine, and colchicine are all inhibitors of collagen cross-linking [3,11].”
BackgroundYoshida, M., Kokubun, T., Sato, K., Tsuda, S., Yokoyama, Y., Himori, N., & Nakazawa, T. (2023) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.64.10.2 · Cited by 16
Zhang, Y., Zhu, S., Xu, X., & Zuo, L. (2019) · Journal of Ophthalmology · doi:10.1155/2019/7419571 · Cited by 17
“Anti-VEGF adjuncts are preliminarily tested in vitro [34], animal studies [12, 35], and small clinical trials [36–40].”
BackgroundEffect of Bevacizumab on Strabismus Surgery in Rabbits
Choi, H. Y., Lee, J. H., Lee, J. E., & Jung, J. H. (2010) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.09-5066 · Cited by 16
Peng, R., Qin, G., Li, X., Lv, H., Qian, Z., & Yu, L. (2014) · Medical Hypothesis Discovery & Innovation in Ophthalmology · Cited by 24
MiR-146a reduces fibrosis after glaucoma filtration surgery in rats
Han, R., Zhong, H., Zhang, Y., Yu, H., Zhang, Y., Huang, S., Yang, Z., & Zhong, Y. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05170-2 · Cited by 14
“…experimented with various biological, chemical and physical approaches to suppress fibroblast proliferation and scar tissue formation, including the inhibition of TGF-β1, vascular endothelial growth factor [22], Rho-associated protein kinase [23], as well as photodynamic therapy [24], and others.”
BackgroundPrzekora, A., Żarnowski, T., & Ginalska, G. (2017) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-017-0034-4 · Cited by 16
Mahdy, R. A., Al-Mosallamy, S., Alaswad, M., Bor’i, A., & El-Haig, W. M. (2015) · Eye · doi:10.1038/eye.2015.182 · Cited by 14
Żarnowski, T., Tulidowicz-Bielak, M., & Klos-Rola (2013) · Clinical ophthalmology · doi:10.2147/opth.s45210 · Cited by 13
“Both animal and human studies have demonstrated this to be effective.(21,25) Similarly, intraoperative injections during revision surgeries for nonfunctional filtration blebs have been shown to increase the chances of a successful outcome.”
BackgroundChen, H.-J., Lin, C. S., Lee, C., & Chen, Y. (2018) · Ophthalmic Research · doi:10.1159/000486576 · Cited by 12
Ji, Q., Qi, B. B., Liu, L., Lao, W., Yang, Z.-H., Wang, G., Yu, G., & Zhong, J. (2013) · Europe PMC (PubMed Central) · doi:10.3980/j.issn.2222-3959.2013.04.07 · Cited by 11
Effect of Mitomycin, Bevacizumab, and 5-Fluorouracil to Inhibit Urethral Fibrosis in a Rabbit Model
Üyetürk, U., Gücük, A., Fırat, T., Kemahlı, E., Kükner, A., & Özyalvaçlı, M. E. (2014) · Journal of Endourology · doi:10.1089/end.2014.0420 · Cited by 10
“reportedly been used to alleviate scar formation after trabeculectomy and laminectomy.(10,11) 5-Fluorouracil (5-FU) is an antimetabolite chemotherapeutic agent that inhibits thymidylatesynthetase and acts on both DNA and RNA synthesis.”
MethodEffects of ranibizumab on the extracellular matrix production by human Tenon's fibroblast
Noh, S. M. M., Kadir, S. H. S. A., Bannur, Z., Froemming, G. R. A., Hasani, N. A. H., Nawawi, H. M., Crowston, J. G., & Vasudevan, S. K. (2014) · Experimental Eye Research · doi:10.1016/j.exer.2014.08.005 · Cited by 10
Fischer, C., Mans, V., Horn, M., Naxer, S., Klettner, A., & van Oterendorp, C. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-19938 · Cited by 9
Jose, P. F.-S., Teixeira, F. J., Barão, R. C., Sousa, D. C., Marques, R., Barata, A. D., Marques‐Neves, C., Alves, M., Papoila, A. L., Stalmans, I., et al. (2021) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2021-319039 · Cited by 8
Miraftabi, A., Nilforushan, N., Darghahi, M., Alemzadeh, S. A., Parsamanesh, M., & Yadgari, M. (2018) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.13191 · Cited by 10
“showed that in the rabbit subconjunctival injection of Bevacizumab could increase bleb survival.(29) If we accept that VEGF directly stimulates both vascular endothelial cells and fibroblasts and may be the link between angiogenesis and scar formation, inhibition of VGEF can reduce fibrosis and may improve the success…”
BackgroundAntiscarring effect of intraoperative bevacizumab in experimental glaucoma filtration surgery
Hilgert, C. R., Hilgert, Á. H., Odashiro, A. N., Odashiro, P. R., & Paranhos, A. (2018) · Arquivos Brasileiros de Oftalmologia · doi:10.5935/0004-2749.20180062 · Cited by 8
“The aim of this study was to determine the effects of bevacizumab and MMC alone and in combination on IOP and the scarring process after modified GFS in rabbits.”
BackgroundInfluentialIntracameral bevacizumab role in trabeculectomy: A 1-year prospective randomized controlled study
Rabina, G., Barequet, D., Mimouni, M., Kurtz, S., Shemesh, G., Rosenblatt, A., & Rosenfeld, E. (2019) · European Journal of Ophthalmology · doi:10.1177/1120672119874682 · Cited by 8
Nikita, E., Moulin, A., Vergados, I. A., Brοuzas, D., & THEODOSSIADIS, P. G. (2017) · Ophthalmology and Therapy · doi:10.1007/s40123-017-0096-4 · Cited by 9
“In keeping with previous studies [19], anterior chamber (AC) depth was shallow on the first postoperative day and was deep in all rabbits by day 7.”
ResultTHE ROLE OF INTRAVITREAL BEVACIZUMAB IN EXPERIMENTAL POSTERIOR PENETRATING EYE INJURY
Mehdizadeh, M., Fattahi, F., Eghtedari, M., Nowroozzadeh, M. H., & Toosi, F. (2010) · Retina · doi:10.1097/iae.0b013e3181e096f3 · Cited by 7
“However, recent studies have shown its advantages as a potent antifibrotic agent to limit ocular scar tissue formation.(12) As previously mentioned, PVR is an intraocular fibroglial proliferation and is associated with some devastating complications after penetrating eye injury.”
BackgroundAndrés‐Guerrero, V., Camacho-Bosca, I., Salazar-Quiñones, L., Ventura-Abreu, N., Molero-Senosiaín, M., Hernández-Ruiz, S., Bernal-Sancho, G., Herrero‐Vanrell, R., & García-Feijóo, J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13060896 · Cited by 7
“As in previously published studies by other authors [27], in this work there were no remarkable differences in the mean IOP reduction among the study groups, partly because”
ResultSun, M. T., Cotton, R. M., Charoenkijkajorn, C., Garcia-Sanchez, J., Dalal, R., Xia, X., Lin, J. H., Singh, K., Goldberg, J. L., & Liu, W. W. (2023) · Ophthalmology Science · doi:10.1016/j.xops.2023.100448 · Cited by 6
Subconjunctival Bevacizumab Injection in Glaucoma Filtering Surgery: A Case Control Series
Wang, J., & Harasymowycz, P. J. (2013) · ISRN Ophthalmology · doi:10.1155/2013/384134 · Cited by 6
“animal studies in rabbits undergoing trabeculectomy have demonstrated the efficacy of bevacizumab in prolonging bleb survival compared to 5-FU injection [14].”
BackgroundKandarakis, S., Kontaxakis, A., Doumazos, L., Petrou, P., Droutsas, K. D., Papaconstantinou, D., & Georgalas, I. (2022) · Cutaneous and Ocular Toxicology · doi:10.1080/15569527.2021.2003376 · Cited by 7
“226 Prostaglandins 17 21 13 – Carbonic anhydrase inhibitors 17 21 13 – IOP before surgery (min, max) 25 (19, 45) 26 (21, 34) 25 (19, 45) 0.”
Subconjunctival Lymphatics Respond to VEGFC and Anti-Metabolites in Rabbit and Mouse Eyes
Lee, J. Y., Wu, J., Liu, Y., Saraswathy, S., Zhou, L., Bu, Q., Su, Y., Choi, D., Park, E., Strohmaier, C., et al. (2022) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.63.10.16 · Cited by 6
“21,22 However, it can be difficult to study rabbits given cost, time, and a lack of suitable reagents.”
Ghanem, A. A. (2011) · Journal of Clinical & Experimental Ophthalmology · doi:10.4172/2155-9570.1000131 · Cited by 6
Bergen, T. V., Jonckx, B., Moons, L., Feyen, J. H. M., & Stalmans, I. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-19725 · Cited by 6
Evaluation of topical bevacizumab as an adjunct to mitomycin C augmented trabeculectomy
Zarei, R., Masoumpour, M. B., Moghimi, S., Fakhraei, G. H., Eslami, Y., & Mohammadi, M. (2016) · Journal of Current Ophthalmology · doi:10.1016/j.joco.2016.10.003 · Cited by 7
“25 mg bevacizumab were compared with subconjunctival 5-FU showed larger and higher blebs with less scar formation.(6) In a pilot study, Kahook observed more diffuse blebs with reduced vascularity in the group with topical MMC and intravitreal ranibizumab compared with topical MMC only.”
BackgroundPostoperative adjunctive bevacizumab versus placebo in primary trabeculectomy surgery for glaucoma
Muhsen, S., Compan, J., Lai, T., Kranemann, C. F., & Birt, C. M. (2019) · International Journal of Ophthalmology · doi:10.18240/ijo.2019.10.08 · Cited by 7
Time Heals All Wounds: Obstacles in Glaucoma Surgery from an Asian Perspective
Toh, Z. H., Lee, C. S. Y., Chew, A. C. Y., & Perera, S. (2015) · Proceedings of Singapore Healthcare · doi:10.1177/201010581502400206 · Cited by 5
Study regarding the survival of patients suffering a traumatic cardiac arrest.
Popescu, V., Leasu, C., Stana, D., Alexandrescu, C., & Dumitrescu, A. (2015) · PubMed Central · Cited by 5
VEGF inhibitors in glaucoma surgery
Mamikonyan, V. R., Petrov, S. Y., & Максимовна, С. Д. (2016) · Ophthalmology Reports · doi:10.17816/ov9147-55 · Cited by 5
VEGF-C and 5-Fluorouracil Improve Bleb Survival in a Rabbit Glaucoma Surgery Trabeculectomy Model
Wu, J., Zhou, L., Liu, Y., Zhang, X., Yang, Y., Zhu, X., Bu, Q., Shan, X., Yin, J., Weinreb, R. N., et al. (2024) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.65.5.32 · Cited by 4
“27–29 Gene expression analysis in this study showed that VEGF-C successfully promoted lymphatics without a change in blood vessels.”
BackgroundResultAnimal models of scarring control
Williams, D. L. (2019) · Eye · doi:10.1038/s41433-019-0727-1 · Cited by 4
A Brief Review of Historical and Current Trends in Trabeculectomy
Pham, A. H., Lees, R., & Gutkind, N. E. (2023) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000484 · Cited by 4
Bevacizumab Promotes T-Cell–Mediated Collagen Deposition in the Mouse Model of Conjunctival Scarring
Seet, L., Toh, L. Z., Chu, S. W. L., Finger, S. N., Ginhoux, F., Hong, W., & Wong, T. T. L. (2018) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.17-22694 · Cited by 4
Öner, A., Kahraman, N., Özdamar, S., & Balcıoğlu, E. (2018) · International Journal of Ophthalmology · doi:10.18240/ijo.2018.04.06 · Cited by 3
Antiangiogene Therapie bei neovaskulärem Glaukom und nach Filterkissenchirurgie
Lüke, J., Lüke, M., & Grisanti, S. (2009) · Der Ophthalmologe · doi:10.1007/s00347-009-1940-2 · Cited by 3
Rangel, H. M. D. A., Rolim, H., Vidigal, P. V. T., Duval-Araújo, I., & Cronemberger, S. (2018) · Revista do Colégio Brasileiro de Cirurgiões · doi:10.1590/0100-6991e-20181861 · Cited by 3
Yoon, S. Y., Kim, E., Han, G. S., Suh, L. H., Jung, H. S., Tchah, H., & Kim, J. Y. (2019) · PLoS ONE · doi:10.1371/journal.pone.0219194 · Cited by 3
Yoon, S. Y., Kim, E., Han, G. S., Suh, L. H., Jung, H. S., Tchah, H., & Kim, J. Y. (2019) · PLoS ONE · doi:10.1371/journal.pone.0226662 · Cited by 3
The Effect of Subconjunctival Bevacizumab on Angiogenesis in Rabbit Model
Nurwasis, N., Yuliawati, D., Komaratih, E., & Heriyawati, H. (2020) · Folia Medica Indonesiana · doi:10.20473/fmi.v55i4.24465 · Cited by 3
Modulation Agents of Wound Healing in Ocular Surgeries
Yaakub, A., Mohd-Yusof, S.-F., Ahmad, A., Yusuf, W. N. W., Low, J. H., Ahmad-Tajudin, L.-S., & Hamzah, J. C. (2024) · Malaysian Journal of Medicine and Health Sciences · doi:10.47836/mjmhs.20.1.37 · Cited by 2
“The effect is further enhanced with the combination with antimetabolite drugs (70–72).”
BackgroundGiral, E. M., Zori, M. R., Martínez, S. P., & Fernández, N. T. (2014) · Archivos de la Sociedad Española de Oftalmología · doi:10.1016/j.oftal.2014.09.010 · Cited by 3
Giral, E. M., Zori, M. R., Martínez, S. P., & Fernández, N. T. (2015) · Archivos de la Sociedad Española de Oftalmología (English Edition) · doi:10.1016/j.oftale.2015.02.012 · Cited by 2
Mohammed, T., Mohamed, M., Abdelshafik, M. A., & Ibiary, H. E. (2015) · Journal of the Egyptian Ophthalmological Society · doi:10.4103/2090-0686.174654 · Cited by 2
Subconjunctival bevacizumab versus mitomycin c as adjuvant treatment to subscleral trabeculectomy
Elkasaby, M. (2018) · The Scientific Journal of Al-Azhar Medical Faculty Girls · doi:10.4103/sjamf.sjamf_18_18 · Cited by 2
Metadata
- Authors
- Memarzadeh, F., Varma, R., Lin, L.-T., Parikh, J. G., Dustin, L., Alcaraz, A., & Eliott, D.
- Affiliations
- Doheny Eye Institute (US)
- University of Southern California (US)
- Armed Forces Sung Shan General Hospital, Taipei, Taiwan, Republic of China; and
- Western University of Health Sciences (US)
- Venue
- Investigative Opthalmology & Visual Science
- Published
- 2009-07-01
- Volume
- 50
- Issue
- 7
- Pages
- 3233
- ISSN
- 0146-0404 (ISSN-L)
- 1552-5783
- OpenAlex
- W2154459059
- Cited by
- 117
- References
- 23
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 4 · 2023: 5 · 2022: 4 · 2021: 5 · 2020: 3 · 2019: 8 · 2018: 8 · 2017: 4 · 2016: 7 · 2015: 11 · 2014: 10 · 2013: 13 · 2012: 11
- FWCI
- 10.50
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Investigative Ophthalmology & Visual Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
- Health Sciences › Medicine › Ophthalmology › Corneal surgery and disorders
- Health Sciences › Medicine › Ophthalmology › Intraocular Surgery and Lenses
- Keywords
- bevacizumab, trabeculectomy, glaucoma filtration surgery, bleb survival, postoperative scarring, antifibrotic therapy, 5-fluorouracil, subconjunctival injection, bleb fibrosis, rabbit model
- MeSH terms
- Bevacizumab, Animals, Antibodies, Monoclonal, Antimetabolites, Antineoplastic, Conjunctiva, Disease Models, Animal, Fibroblasts, Fibrosis, Fluorouracil, Glaucoma, Injections, Intraocular Pressure, Postoperative Care, Prognosis, Rabbits, Sclera, Trabeculectomy, Wound Healing, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.